RxDoctor Payments Data

Melissa Watkins

Gerontology · Dothan, ALNPI 1477093102

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 423 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by GSK at 25.1% of the total. Among gerontology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,375in general payments, 2019–2025

Across 423 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Boehringer Ingelheim$1K
  • AstraZeneca$1K
  • Amgen$503
  • Takeda Pharmaceuticals U.S.A., Inc.$460
  • Sanofi$344
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$8,31899%
  • Education$571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,375 in reported general payments places this provider in the 95th percentile of 143 gerontology providers in Alabama.

See all gerontology providers in Alabama

Medicare billing

Part B allowed, 2024
$94,621
Medicare patients
577
Services billed
1,335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate66$904,655
Trelegy ElliptaFluticasone/Umeclidin/Vilanter842$718,144
Breztri AerosphereBudesonide/Glycopyr/Formoterol169$144,622
Breo ElliptaFluticasone/Vilanterol168$88,950
Dupixent SyringeDupilumab13$57,382
Stiolto RespimatTiotropium Br/Olodaterol Hcl46$30,272
Spiriva RespimatTiotropium Bromide48$26,535
Combivent RespimatIpratropium/Albuterol Sulfate28$24,346
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$17,496
SymbicortBudesonide/Formoterol Fumarate45$16,624
Advair HfaFluticasone Propion/Salmeterol34$15,002
Incruse ElliptaUmeclidinium Bromide31$10,685
Fluticasone-SalmeterolFluticasone Propion/Salmeterol59$9,819
Albuterol Sulfate HfaAlbuterol Sulfate396$8,886
Arnuity ElliptaFluticasone Furoate32$7,982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat$1,469$985,808188 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$2,100$843,2561,099 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,098$161,246214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 143 gerontology providers in Alabama.

Other gerontology in Dothan

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →